-
1
-
-
84855792427
-
Cancer statistics, 2012
-
22237781 10.3322/caac.20138
-
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29
-
(2012)
CA Cancer J Clin
, vol.62
, Issue.1
, pp. 10-29
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
2
-
-
0025974356
-
Carcinoma of the prostate
-
1985245 10.1056/NEJM199101243240406 1:STN:280:DyaK3M%2Foslyqsw%3D%3D
-
Gittes RF (1991) Carcinoma of the prostate. N Engl J Med 324(4):236-245
-
(1991)
N Engl J Med
, vol.324
, Issue.4
, pp. 236-245
-
-
Gittes, R.F.1
-
3
-
-
0024324367
-
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
-
2503724 10.1056/NEJM198908173210702 1:STN:280:DyaL1MzksVWgtw%3D%3D
-
Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321(7):419-424
-
(1989)
N Engl J Med
, vol.321
, Issue.7
, pp. 419-424
-
-
Crawford, E.D.1
Eisenberger, M.A.2
McLeod, D.G.3
Spaulding, J.T.4
Benson, R.5
Dorr, F.A.6
Blumenstein, B.A.7
Davis, M.A.8
Goodman, P.J.9
-
4
-
-
0027203411
-
Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
-
7687666 1:STN:280:DyaK3szivFGjsA%3D%3D
-
Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11(8):1566-1572
-
(1993)
J Clin Oncol
, vol.11
, Issue.8
, pp. 1566-1572
-
-
Scher, H.I.1
Kelly, W.K.2
-
5
-
-
0029084601
-
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer
-
8620419 10.1002/1097-0142(19951015)76:8<1428: AID-CNCR2820760820>3. 0.CO;2-T 1:STN:280:DyaK283itlWqtQ%3D%3D
-
Small EJ, Srinivas S (1995) The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76(8):1428-1434
-
(1995)
Cancer
, vol.76
, Issue.8
, pp. 1428-1434
-
-
Small, E.J.1
Srinivas, S.2
-
6
-
-
0031001274
-
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade
-
9112515 10.1016/S0022-5347(01)64846-8 1:CAS:528:DyaK2sXmtVGjtrg%3D
-
Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJ (1997) Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157(5):1731-1735
-
(1997)
J Urol
, vol.157
, Issue.5
, pp. 1731-1735
-
-
Schellhammer, P.F.1
Venner, P.2
Haas, G.P.3
Small, E.J.4
Nieh, P.T.5
Seabaugh, D.R.6
Patterson, A.L.7
Klein, E.8
Wajsman, Z.9
Furr, B.10
Chen, Y.11
Kolvenbag, G.J.12
-
7
-
-
0029808474
-
Clinical trials in relapsed prostate cancer: Defining the target
-
8931606 10.1093/jnci/88.22.1623 1:CAS:528:DyaK2sXjs1egug%3D%3D
-
Scher HI, Mazumdar M, Kelly WK (1996) Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 88(22):1623-1634
-
(1996)
J Natl Cancer Inst
, vol.88
, Issue.22
, pp. 1623-1634
-
-
Scher, H.I.1
Mazumdar, M.2
Kelly, W.K.3
-
8
-
-
0031017228
-
Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
-
8996165 1:CAS:528:DyaK2sXnsV2ltg%3D%3D
-
Small EJ, Vogelzang NJ (1997) Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 15(1):382-388
-
(1997)
J Clin Oncol
, vol.15
, Issue.1
, pp. 382-388
-
-
Small, E.J.1
Vogelzang, N.J.2
-
9
-
-
11144229621
-
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer
-
15623588 10.1158/1078-0432.CCR-04-1402 1:CAS:528:DC%2BD2cXhtFGjsrrE
-
Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R (2004) Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 10(24):8147-8151
-
(2004)
Clin Cancer Res
, vol.10
, Issue.24
, pp. 8147-8151
-
-
Dagher, R.1
Li, N.2
Abraham, S.3
Rahman, A.4
Sridhara, R.5
Pazdur, R.6
-
10
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
TAX 327 Investigators 15470213 10.1056/NEJMoa040720 1:CAS:528: DC%2BD2cXot1Kmu7s%3D
-
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502-1512
-
(2004)
N Engl J Med
, vol.351
, Issue.15
, pp. 1502-1512
-
-
Tannock, I.F.1
De Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Théodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
11
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
IMPACT Study Investigators 20818862 10.1056/NEJMoa1001294 1:CAS:528:DC%2BC3cXhtVGlurrN
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411-422
-
(2010)
N Engl J Med
, vol.363
, Issue.5
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
Redfern, C.H.7
Ferrari, A.C.8
Dreicer, R.9
Sims, R.B.10
Xu, Y.11
Frohlich, M.W.12
Schellhammer, P.F.13
-
12
-
-
77949895922
-
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
-
20100959 10.1200/JCO.2009.25.0597 1:CAS:528:DC%2BC3cXktF2ltLw%3D
-
Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28(7):1099-1105
-
(2010)
J Clin Oncol
, vol.28
, Issue.7
, pp. 1099-1105
-
-
Kantoff, P.W.1
Schuetz, T.J.2
Blumenstein, B.A.3
Glode, L.M.4
Bilhartz, D.L.5
Wyand, M.6
Manson, K.7
Panicali, D.L.8
Laus, R.9
Schlom, J.10
Dahut, W.L.11
Arlen, P.M.12
Gulley, J.L.13
Godfrey, W.R.14
-
13
-
-
0025109257
-
Immunohistological distribution of 5T4 antigen in normal and malignant tissues
-
2404511 10.1038/bjc.1990.20 1:STN:280:DyaK3c7it1GrtQ%3D%3D
-
Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL (1990) Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61:89-95
-
(1990)
Br J Cancer
, vol.61
, pp. 89-95
-
-
Southall, P.J.1
Boxer, G.M.2
Bagshawe, K.D.3
Hole, N.4
Bromley, M.5
Stern, P.L.6
-
14
-
-
0028324131
-
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma
-
8180020 10.1038/bjc.1994.173 1:STN:280:DyaK2c3jsFCntg%3D%3D
-
Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL (1994) Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 69:899-902
-
(1994)
Br J Cancer
, vol.69
, pp. 899-902
-
-
Starzynska, T.1
Marsh, P.J.2
Schofield, P.F.3
Roberts, S.A.4
Myers, K.A.5
Stern, P.L.6
-
15
-
-
79958819359
-
Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells
-
21540235 10.1158/0008-5472.CAN-10-3919 1:CAS:528:DC%2BC3MXnsFKht70%3D
-
Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, DiJoseph JF, Karnoub M, Huang S, Diesl V, Behrens C, Choe SE, Rios C, Gruzas J, Sridharan L, Dougher M, Kunz A, Hamann PR, Evans D, Armellino D, Khandke K, Marquette K, Tchistiakova L, Boghaert ER, Abraham RT, Wistuba II, Zhou BB (2011) Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 71:4236-4246
-
(2011)
Cancer Res
, vol.71
, pp. 4236-4246
-
-
Damelin, M.1
Geles, K.G.2
Follettie, M.T.3
Yuan, P.4
Baxter, M.5
Golas, J.6
Dijoseph, J.F.7
Karnoub, M.8
Huang, S.9
Diesl, V.10
Behrens, C.11
Choe, S.E.12
Rios, C.13
Gruzas, J.14
Sridharan, L.15
Dougher, M.16
Kunz, A.17
Hamann, P.R.18
Evans, D.19
Armellino, D.20
Khandke, K.21
Marquette, K.22
Tchistiakova, L.23
Boghaert, E.R.24
Abraham, R.T.25
Wistuba, I.I.26
Zhou, B.B.27
more..
-
16
-
-
48549088424
-
Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): A phase 2 trial
-
18528296 10.1097/CJI.0b013e31817deafd 1:CAS:528:DC%2BD1cXnslKjt74%3D
-
Amato RJ, Drury N, Naylor S, Jac J, Saxena S, Cao A, Hernandez-McClain J, Harrop R (2008) Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 31:577-585
-
(2008)
J Immunother
, vol.31
, pp. 577-585
-
-
Amato, R.J.1
Drury, N.2
Naylor, S.3
Jac, J.4
Saxena, S.5
Cao, A.6
Hernandez-Mcclain, J.7
Harrop, R.8
-
17
-
-
33745223435
-
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial
-
16740766 10.1158/1078-0432.CCR-05-2732 1:CAS:528:DC%2BD28XltFyis7c%3D
-
Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, Carroll MW (2006) Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12:3416-3424
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3416-3424
-
-
Harrop, R.1
Connolly, N.2
Redchenko, I.3
Valle, J.4
Saunders, M.5
Ryan, M.G.6
Myers, K.A.7
Drury, N.8
Kingsman, S.M.9
Hawkins, R.E.10
Carroll, M.W.11
-
18
-
-
34547652648
-
Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses
-
17671134 10.1158/1078-0432.CCR-07-0704 1:CAS:528:DC%2BD2sXotlGqtb0%3D
-
Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, Wassan H, Habib N, Anthoney A (2007) Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 13:4487-4494
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4487-4494
-
-
Harrop, R.1
Drury, N.2
Shingler, W.3
Chikoti, P.4
Redchenko, I.5
Carroll, M.W.6
Kingsman, S.M.7
Naylor, S.8
Melcher, A.9
Nicholls, J.10
Wassan, H.11
Habib, N.12
Anthoney, A.13
-
19
-
-
42649138944
-
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses
-
18060404 10.1007/s00262-007-0428-7 1:CAS:528:DC%2BD1cXltFeqtLg%3D
-
Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, Hawkins RE (2008) Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 57:977-986
-
(2008)
Cancer Immunol Immunother
, vol.57
, pp. 977-986
-
-
Harrop, R.1
Drury, N.2
Shingler, W.3
Chikoti, P.4
Redchenko, I.5
Carroll, M.W.6
Kingsman, S.M.7
Naylor, S.8
Griffiths, R.9
Steven, N.10
Hawkins, R.E.11
-
20
-
-
67650136139
-
An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases
-
18833005 10.1097/CJI.0b013e3181876ab3 1:CAS:528:DC%2BD1cXht1OksL7I
-
Elkord E, Dangoor A, Drury NL, Harrop R, Burt DJ, Drijfhout JW, Hamer C, Andrews D, Naylor S, Sherlock D, Hawkins RE, Stern PL (2008) An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother 31:820-829
-
(2008)
J Immunother
, vol.31
, pp. 820-829
-
-
Elkord, E.1
Dangoor, A.2
Drury, N.L.3
Harrop, R.4
Burt, D.J.5
Drijfhout, J.W.6
Hamer, C.7
Andrews, D.8
Naylor, S.9
Sherlock, D.10
Hawkins, R.E.11
Stern, P.L.12
-
21
-
-
58149354757
-
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: A phase II trial
-
19010868 10.1158/1078-0432.CCR-08-0668 1:CAS:528:DC%2BD1cXhtlylur3M
-
Amato RJ, Shingler W, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R (2008) Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res 14:7504-7510
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7504-7510
-
-
Amato, R.J.1
Shingler, W.2
Naylor, S.3
Jac, J.4
Willis, J.5
Saxena, S.6
Hernandez-Mcclain, J.7
Harrop, R.8
-
22
-
-
68449100522
-
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): A phase 2 trial
-
19561532 10.1097/CJI.0b013e3181ace876 1:CAS:528:DC%2BD1MXovFSis7w%3D
-
Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R (2009) Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 32:765-772
-
(2009)
J Immunother
, vol.32
, pp. 765-772
-
-
Amato, R.J.1
Shingler, W.2
Goonewardena, M.3
De Belin, J.4
Naylor, S.5
Jac, J.6
Willis, J.7
Saxena, S.8
Hernandez-Mcclain, J.9
Harrop, R.10
-
23
-
-
67449085969
-
Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha
-
19342962 10.1097/CJI.0b013e31819d297e 1:CAS:528:DC%2BD1MXkvVGmtr4%3D
-
Hawkins RE, Macdermott C, Shablak A, Hamer C, Thistlethwaite F, Drury NL, Chikoti P, Shingler W, Naylor S, Harrop R (2009) Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother 32:424-429
-
(2009)
J Immunother
, vol.32
, pp. 424-429
-
-
Hawkins, R.E.1
Macdermott, C.2
Shablak, A.3
Hamer, C.4
Thistlethwaite, F.5
Drury, N.L.6
Chikoti, P.7
Shingler, W.8
Naylor, S.9
Harrop, R.10
-
24
-
-
60549106426
-
Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
-
19128501 10.1186/1479-5876-7-2
-
Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S (2009) Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 7:2
-
(2009)
J Transl Med
, vol.7
, pp. 2
-
-
Kaufman, H.L.1
Taback, B.2
Sherman, W.3
Kim, D.W.4
Shingler, W.H.5
Moroziewicz, D.6
Deraffele, G.7
Mitcham, J.8
Carroll, M.W.9
Harrop, R.10
Naylor, S.11
Kim-Schulze, S.12
-
25
-
-
78349284842
-
Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled phase III study
-
20881001 10.1158/1078-0432.CCR-10-2082 1:CAS:528:DC%2BC3cXhsVWmsbnN
-
Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, McDonald M, Eastty S, Shingler WH, de Belin J, Goonewardena M, Naylor S, Harrop R (2010) Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 16:5539-5547
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5539-5547
-
-
Amato, R.J.1
Hawkins, R.E.2
Kaufman, H.L.3
Thompson, J.A.4
Tomczak, P.5
Szczylik, C.6
McDonald, M.7
Eastty, S.8
Shingler, W.H.9
De Belin, J.10
Goonewardena, M.11
Naylor, S.12
Harrop, R.13
-
26
-
-
79959699551
-
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients
-
21387109 10.1007/s00262-011-0993-7 1:CAS:528:DC%2BC3MXmsVajtLw%3D
-
Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, Kaufman HL, de Belin J, Kelleher M, Goonewardena M, Naylor S (2011) MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother 60:829-837
-
(2011)
Cancer Immunol Immunother
, vol.60
, pp. 829-837
-
-
Harrop, R.1
Shingler, W.H.2
McDonald, M.3
Treasure, P.4
Amato, R.J.5
Hawkins, R.E.6
Kaufman, H.L.7
De Belin, J.8
Kelleher, M.9
Goonewardena, M.10
Naylor, S.11
-
27
-
-
84871004671
-
Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)
-
22692758 10.1007/s00262-012-1302-9 1:CAS:528:DC%2BC38XhslKhsbbJ
-
Harrop R, Treasure P, de Belin J, Kelleher M, Bolton G, Naylor S, Shingler WH (2012) Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). Cancer Immunol Immunother 61(12):2283-2294
-
(2012)
Cancer Immunol Immunother
, vol.61
, Issue.12
, pp. 2283-2294
-
-
Harrop, R.1
Treasure, P.2
De Belin, J.3
Kelleher, M.4
Bolton, G.5
Naylor, S.6
Shingler, W.H.7
-
28
-
-
84865553173
-
Combination immunotherapy approaches
-
doi: 10.1093/annonc/mds262
-
Drake CG (2012) Combination immunotherapy approaches. Ann Oncol (Suppl 8):viii41-viii46. doi: 10.1093/annonc/mds262
-
(2012)
Ann Oncol
, Issue.SUPPL. 8
-
-
Drake, C.G.1
-
29
-
-
0033942857
-
The immunological effects of taxanes
-
10941900 10.1007/s002620000122 1:CAS:528:DC%2BD3cXlvFymsb8%3D
-
Chan OT, Yang LX (2000) The immunological effects of taxanes. Cancer Immunol Immunother 49(4-5):181-185
-
(2000)
Cancer Immunol Immunother
, vol.49
, Issue.4-5
, pp. 181-185
-
-
Chan, O.T.1
Yang, L.X.2
-
30
-
-
0035286721
-
Enhancement of tumor radioresponse by docetaxel: Involvement of immune system
-
11179493 1:CAS:528:DC%2BD3MXhsFGlt7Y%3D
-
Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, Milas L (2001) Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18(3):599-606
-
(2001)
Int J Oncol
, vol.18
, Issue.3
, pp. 599-606
-
-
Mason, K.1
Staab, A.2
Hunter, N.3
McBride, W.4
Petersen, S.5
Terry, N.6
Milas, L.7
-
31
-
-
33644760431
-
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
-
16489082 10.1158/1078-0432.CCR-05-2059 1:CAS:528:DC%2BD28XhsFaltb8%3D
-
Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4):1260-1269
-
(2006)
Clin Cancer Res
, vol.12
, Issue.4
, pp. 1260-1269
-
-
Arlen, P.M.1
Gulley, J.L.2
Parker, C.3
Skarupa, L.4
Pazdur, M.5
Panicali, D.6
Beetham, P.7
Tsang, K.Y.8
Grosenbach, D.W.9
Feldman, J.10
Steinberg, S.M.11
Jones, E.12
Chen, C.13
Marte, J.14
Schlom, J.15
Dahut, W.16
-
32
-
-
50349091770
-
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumour activity: Effects of docetaxel on immune enhancement
-
10.1158/1078-0432.CCR-07-4025 1:CAS:528:DC%2BD1cXmslygtrc%3D
-
Garnett CT, Schlom J, Hodge JW (2008) Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumour activity: effects of docetaxel on immune enhancement. Clin Can Res 14(11):3536-3544
-
(2008)
Clin Can Res
, vol.14
, Issue.11
, pp. 3536-3544
-
-
Garnett, C.T.1
Schlom, J.2
Hodge, J.W.3
-
33
-
-
41949104346
-
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
-
Prostate Cancer Clinical Trials Working Group 18309951 10.1200/JCO.2007.12.4487
-
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26(7):1148-1159
-
(2008)
J Clin Oncol
, vol.26
, Issue.7
, pp. 1148-1159
-
-
Scher, H.I.1
Halabi, S.2
Tannock, I.3
Morris, M.4
Sternberg, C.N.5
Carducci, M.A.6
Eisenberger, M.A.7
Higano, C.8
Bubley, G.J.9
Dreicer, R.10
Petrylak, D.11
Kantoff, P.12
Basch, E.13
Kelly, W.K.14
Figg, W.D.15
Small, E.J.16
Beer, T.M.17
Wilding, G.18
Martin, A.19
Hussain, M.20
more..
-
34
-
-
77957787538
-
Therapeutic cancer vaccines in prostate cancer: The paradox of improved survival without changes in time to progression
-
20798195 10.1634/theoncologist.2010-0129
-
Madan RA, Gulley JL, Fojo T, Dahut WL (2010) Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15(9):969-975
-
(2010)
Oncologist
, vol.15
, Issue.9
, pp. 969-975
-
-
Madan, R.A.1
Gulley, J.L.2
Fojo, T.3
Dahut, W.L.4
-
35
-
-
84877102343
-
Cancer vaccines: Identification of biomarkers predictive of clinical efficacy
-
10.4161/hv.23032
-
Harrop R (2013) Cancer vaccines: identification of biomarkers predictive of clinical efficacy. Hum Vaccin Immunother 9(4):1-5
-
(2013)
Hum Vaccin Immunother
, vol.9
, Issue.4
, pp. 1-5
-
-
Harrop, R.1
|